A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer (NCT07652073) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
China30 participantsStarted 2026-06-15
Plain-language summary
This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* sign a written informed consent form
* At least 18 years of age (inclusive)
* Epithelial ovarian cancer confirmed by histopathology or cytopathology
* BRCA1/2 mutation or HRD-positive status
* Patients who have failed standard treatment or are unable to tolerate standard treatment
* Patients must have received no more than five prior treatment lines
* At least one measurable lesion
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
* Bone marrow reserve and organ function must meet the requirements
* Negative result on a blood pregnancy test for a woman of childbearing age
Exclusion Criteria:
* Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 half-lives prior to the first dose
* Received treatment with an anticancer biological therapy within 4 weeks prior to the first dose
* Underwent major surgery within 4 weeks prior to the first dose
* Has previously received treatment with a PARG inhibitor
* Inadequate response to previous PARP inhibitor maintenance therapy
* With central nervous system metastases
* Patients with clinically significant cardiovascular or cerebrovascular diseases
* Uncontrolled active infections requiring intravenous antibiotics or hospitalization
* Adverse reactions from prior anticancer therapy have not yet resolved to a grade ≤1
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.